Shots:

• The P-I ALPHA study of ALLO-501 produced durable CR with the longest ongoing CR @15mos. in both LBCL and FL. ORR (75%) and CR (50%) across histologies in CAR T naïve patients- on par with data from pivotal trials of autologous CAR T therapies
• The APLHA-2 data demonstrated comparable efficacy & safety for ALLO-501A relative to ALLO-501. The consolidation dosing was well tolerated and showed early promise with 4 patients converting from PR to CR following the second dose of ALLO-501 or ALLO-501A
• The data will be presented at ASCO 2021. The company plan to initiate the pivotal trial of ALLO-501A in late 2021

  Ref: Allogene | Image: Allogene